Almirall S.A. announced the commercial launch in Germany and the UK of Klisyri (tirbanibulin), approved by the European Commission and the UK Medicines & Healthcare products Regulatory Agency (MHRA) in July and August of 2021, respectively, for the topical treatment of actinic keratosis (AK) of the face and scalp in adults. Klisyri® (tirbanibulin) is a novel, topical first-in-class microtubule inhibitor with a selective antiproliferative mechanism of action that represents a significant step forward in the treatment of AK due to its short treatment protocol - one application daily for 5 days - proven efficacy and safety profile, with very acceptable local tolerability. AK is a common skin condition caused by sun damage occurring mostly in zones that are chronically exposed to ultraviolet (UV) radiation. During the last years, its incidence has gone up due to an aging population, increased exposure to UV radiation, and changes in UV-seeking behaviors[3] and is one of the most common diagnoses made by dermatologists in Europe. Its prevalence can be calculated to be around 18% of the population in this continent. Data reported in the UK estimates a very similar prevalence, around 19-24% of the population over the age of 60 years. In Germany, the estimated annual number of AK cases documented by dermatologists is about 1.7 million. The MHRA approved Klisyri® following the approval of the European Commission in the EU in July 2021, and based on two pivotal phase III studies' (KX01-AK-003 and KX01-AK-004) positive results, published in the New England Journal of Medicine (NEJM). These two, double-blind, vehicle-controlled, randomised, parallel-group, multi-centre phase III clinical trials included 702 patients from 62 clinical sites across the US, and demonstrated that once-daily application of tirbanibulin ointment 1% (10 mg/g) for 5 consecutive days in adults with AK on the face or scalp is effective and generally well tolerated. Tirbanibulin met the primary endpoint, which was defined as 100% clearance of AK lesions at Day 57 within the face or scalp treatment areas, each study achieving a highly statistically significant result (p<0.0001).